엘라스토머 주입 펌프 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Elastomeric Infusion Pumps Market Size, Share & Trends Analysis Report By Product (Continuous Rate Elastomeric Infusion Pumps, Variable Rate Elastomeric Infusion Pumps), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,590,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,034,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,922,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

엘라스토머 주입 펌프 시장 동향 :

세계의 엘라스토머 주입 펌프 시장 규모는 2024년에 6억 7,980만 달러로 추계되었습니다. 2025년부터 2030년에 걸쳐 CAGR 7.2%를 나타낼 것으로 예측됩니다.

암, 당뇨병, 심혈관 장애 등의 만성 질환의 이환율이 상승하고 있는 것이 시장 성장의 큰 촉진요인이 되고 있습니다. 세계 보건기구(WHO) 통계에 따르면 만성 질환은 세계 사망 원인의 최상위이며 전 세계 사망 원인의 71%를 차지합니다. 따라서 이러한 질병의 효과적인 치료와 관리를 보장하기 위해 엘라스토머 펌프와 같은 연속 약물전달 시스템에 대한 수요가 증가하고 있습니다.

가정 의료 솔루션에 대한 수요 증가는 엘라스토머 주입 펌프 산업을 견인하는 중요한 요소입니다. 환자는 집에서 약물을 투여 할 수있는 치료법을 선호하며 엘라스토머 펌프의 휴대성과 사용 편의성은 이러한 요구에 부응합니다. 이 추세는 고령화에 의한 만성 질환의 장기 치료에 대한 요구가 증가함에 따라 더욱 강해지고 있습니다. 2024년 10월에 발표된 연구에 따르면, 골수염은 미국에서 연간 약 50,000명이 앓고 있으며, 소아, 노인, 남성의 이환율이 높다고 합니다. 척추골과 장골이 가장 잘 앓는 부위입니다. 또한 골수염은 여성보다 남성이 병에 걸리기 쉽다는 것이 현재의 조사와이 질병에 관한 다른 발표 데이터에서 밝혀졌습니다.

제조업체는 시장 성장을 가속하기 위해 엘라스토머 주입 펌프 기술의 강화에 주력하고 있습니다. 이러한 발전에는 보다 높은 정밀도, 더 긴 주입 시간, 개선된 기능을 갖춘 펌프 개발, 사용하기 쉬운 디자인 등이 포함됩니다. 이러한 기술 혁신은 환자와 의료 제공업체의 다양한 요구에 대응하고 엘라스토머 주입 펌프의 효율을 높이고 신뢰성과 안전성을 높이는 것을 목표로 하고 있습니다. 2024년 9월 Journal of Biosciences and Medicines 잡지에 게재된 연구에서는 카테터를 통해 약물을 공급하는 엘라스토머 펌프의 이론 모델이 발표되었습니다. 이 연구에서는 임상 유량을 정확하게 재현하고 구체 반경과 관련된 독성 범프를 확인했습니다. 연구자들은 펌프의 특성을 최적화함으로써 독성의 영향을 최소화하면서 주입 시간을 제어할 수 있다고 결론지었습니다.

오피오이드 의존성을 줄이고 대체 통증 관리 솔루션에 대한 환자 접근을 개선하려는 움직임이 커지고 있다는 것은 의료 정책의 변화에 큰 추진력이되었습니다. 2024년 11월, Avanos Medical, Inc.는 메디케어 메디케이드 서비스 센터가 2025년 메디케어 병원 외래 환자 긍정적인 지불 시스템 및 외래수술센터(ASC) 지불 시스템 규칙을 최종 결정하고 2025년 1월 1일에 발효한다고 보고했습니다. 이 업데이트에서는 NOPAIN 방법이 도입되었으며 Medicare는 병원 외래 및 수술센터 환경에서 통증 관리 솔루션에 대한 환자 액세스를 개선하기 위해 대상 비오피오이드 의약품 및 장비에 대한 명확한 지불을 요구합니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 엘라스토머 주입 펌프 시장 : 변동 요인·경향·범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 엘라스토머 주입 펌프 시장 : 분석 툴
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 엘라스토머 주입 펌프 시장 : 제품별 추정·동향 분석

• 세계의 엘라스토머 주입 펌프 시장 : 제품별 대시보드
• 세계의 엘라스토머 주입 펌프 시장 : 제품별 변동 분석
• 세계의 엘라스토머 주입 펌프 시장 : 제품별(수익 기준)
• 정속식 엘라스토머 주입 펌프
• 변속식 엘라스토머 주입 펌프

제5장 엘라스토머 주입 펌프 시장 : 용도별 추정·동향 분석

• 세계의 엘라스토머 주입 펌프 시장 : 용도별 대시보드
• 세계의 엘라스토머 주입 펌프 시장 : 용도별 변동 분석
• 세계의 엘라스토머 주입 펌프 시장 : 용도별(수익 기준)
• 통증 관리
• 화학요법
• 항생제/항바이러스 요법
• 기타

제6장 엘라스토머 주입 펌프 시장 : 최종 용도별 추정·동향 분석

• 세계의 엘라스토머 주입 펌프 시장 : 최종 용도별 대시보드
• 세계의 엘라스토머 주입 펌프 시장 : 최종 용도별 변동 분석
• 세계의 엘라스토머 주입 펌프 시장 : 최종 용도별(수익 기준)
• 병원
• 외래수술센터(ASC)
• 기타

제7장 엘라스토머 주입 펌프 시장 : 지역별 추정·동향 분석(국가별·제품별·용도별·최종 용도별)

• 지역별 대시보드
• 시장 규모의 예측과 동향 분석(2018년·2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 최신 동향과 영향 분석 : 주요 제조업체별
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 유통업체·채널 파트너 일람
  • 주요 고객
  • 주요 기업의 시장 점유율 분석(2024년)
• 기업 프로파일
  • Baxter
  • Fresenius Kabi AG
  • B. Braun SE
  • Ambu A/S
  • Leventon, SAU
  • NIPRO
  • Terumo Corporation
  • AVNS
  • Vygon Group
  • Smiths Group plc

KTH

영문 목차

영문목차

Elastomeric Infusion Pumps Market Trends:

The global elastomeric infusion pumps market size was estimated at USD 679.8 million in 2024 and is projected to grow at a CAGR of 7.2% from 2025 to 2030. The rising incidence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is a significant driver for market growth. According to statistics from the World Health Organization (WHO), chronic diseases are the leading cause of mortality worldwide, accounting for 71% of all deaths globally. This led to a higher demand for continuous drug delivery systems such as elastomeric pumps to ensure effective treatment and management of these conditions.

The growing demand for home healthcare solutions is a crucial factor driving the elastomeric infusion pumps industry. Patients prefer therapies that enable them to administer medications at home, and the portability and user-friendliness of elastomeric pumps cater to this need. This trend is amplified by the aging population's increasing requirement for long-term treatment of chronic conditions. According to a study published in October 2024, Osteomyelitis affects around 50,000 people annually in the U.S., with higher incidence in children, older adults, and males. Vertebrae and long bones are the most commonly involved sites. It also shows that males are more susceptible to Osteomyelitis than females, as evidenced by the current research and other published data on the disease.

Manufacturers are focusing on enhancing elastomeric infusion pump technologies to drive market growth. These advancements involve greater accuracy, longer infusion durations, developing pumps with improved features, and accessible designs. These innovations aim to cater to the diverse needs of patients and healthcare providers, enhancing the efficiency of elastomeric infusion pumps and making them dependable and secure. In September 2024, research published in the Journal of Biosciences and Medicines presented a theoretical model for elastomeric pumps, which deliver medications through a catheter. The study accurately reproduced clinical flow rates and identified a toxicity bump related to the sphere's radius. The researchers concluded that by optimizing pump properties, infusion times can be controlled while minimizing toxicity effects.

The increasing push to reduce opioid dependence and improve patient access to alternative pain management solutions has been a major driver in healthcare policy changes. In November 2024, Avanos Medical, Inc. reported that the Centers for Medicare and Medicaid Services has finalized its Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System regulations for 2025, set to take effect on January 1, 2025. This update introduces the NOPAIN Act, which requires Medicare to provide distinct payments for eligible non-opioid medications and devices to improve patient access to pain management solutions in hospital outpatient and surgical center environments.

Global Elastomeric Infusion Pumps Market Report Segmentation

This report forecasts revenue growth at global, regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global elastomeric infusion pumps market report based on product, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Continuous Rate Elastomeric Infusion Pumps
• Variable Rate Elastomeric Infusion Pumps
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Pain Management
• Chemotherapy
• Antibiotic/Antiviral Therapy
• Others
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Ambulatory Surgical Centers
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End use outlook
• 2.3. Competitive Insights

Chapter 3. Elastomeric Infusion Pumps Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases
    • 3.2.1.2. Rising number of orthopedic surgeries
    • 3.2.1.3. Technological advancements in elastomeric infusion pumps
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of elastomeric infusion pumps
    • 3.2.2.2. Regulatory standards
• 3.3. Elastomeric Infusion Pumps Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Elastomeric Infusion Pumps Market: Product Estimates & Trend Analysis

• 4.1. Global Elastomeric Infusion Pumps Market: Product Dashboard
• 4.2. Global Elastomeric Infusion Pumps Market: Product Movement Analysis
• 4.3. Global Elastomeric Infusion Pumps Market by Product, Revenue
• 4.4. Continuous Rate Elastomeric Infusion Pumps
  • 4.4.1. Continuous Rate Elastomeric Infusion Pumps market estimates and forecasts, 2018 to 2030 (USD Billion)
• 4.5. Variable Rate Elastomeric Infusion Pumps
  • 4.5.1. Variable Rate Elastomeric Infusion Pumps market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 5. Elastomeric Infusion Pumps Market: Application Estimates & Trend Analysis

• 5.1. Global Elastomeric Infusion Pumps Market: Application Dashboard
• 5.2. Global Elastomeric Infusion Pumps Market: Application Movement Analysis
• 5.3. Global Elastomeric Infusion Pumps Market by Application, Revenue
• 5.4. Pain Management
  • 5.4.1. Pain management market estimates and forecasts, 2018 to 2030 (USD Billion)
• 5.5. Chemotherapy
  • 5.5.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Billion)
• 5.6. Antibiotic/Antiviral Therapy
  • 5.6.1. Antibiotic/antiviral therapy market estimates and forecasts, 2018 to 2030 (USD Billion)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 6. Elastomeric Infusion Pumps Market: End Use Estimates & Trend Analysis

• 6.1. Global Elastomeric Infusion Pumps Market: End Use Dashboard
• 6.2. Global Elastomeric Infusion Pumps Market: End Use Movement Analysis
• 6.3. Global Elastomeric Infusion Pumps Market by End Use, Revenue
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Billion)
• 6.5. Ambulatory Surgical Centers
  • 6.5.1. Ambulatory surgical centers market estimates and forecasts, 2018 to 2030 (USD Billion)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 7. Elastomeric Infusion Pumps Market: Regional Estimates & Trend Analysis by Country, Product, Application and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Baxter
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Fresenius Kabi AG
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. B. Braun SE
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Ambu A/S
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Leventon, S.A.U.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. NIPRO
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Terumo Corporation
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. AVNS
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Vygon Group
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Smiths Group plc
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives

관련자료